New drug shows promise in shrinking eye cancer before surgery

NCT ID NCT05187884

Completed Disease control Sponsor: St Vincent's Hospital, Sydney Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested the drug darovasertib in 15 people with high-risk uveal melanoma (a rare eye cancer) who were scheduled for eye removal surgery. Participants took the drug for up to 4 weeks before surgery, and some continued for 6 months afterward. The main goals were to check safety and see if the drug could shrink the tumor or delay cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Darovasertib (oral tablet)
What this could lead to: If successful, this could point toward a new treatment option to reduce the risk of uveal melanoma returning after eye removal surgery.
What could go wrong: This is a very small, early-phase trial with only 15 participants. It primarily tests safety and tolerability, not effectiveness. The drug may not shrink tumors or prevent recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULAR MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ocular melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OCULAR MELANOMA

Contacts and locations

Locations

Alfred Hospital

Melbourne, Victoria, 3004, Australia
Kinghorn Cancer Centre, St. Vincent's Hospital

Sydney, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.